.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,958,961

« Back to Dashboard

Claims for Patent: 5,958,961

Title: Pharmaceutical composition for angiotensin II-mediated diseases
Abstract:This invention relates to a pharmaceutical composition for angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR1## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with a compound having diuretic activity or a compound having calcium antagonistic activity.
Inventor(s): Inada; Yoshiyuki (Kawanishi, JP), Kubo; Keiji (Riverside, CA)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Application Number:08/883,040
Patent Claims: 1. A pharmaceutical composition for treating angiotensin II-mediated diseases, which comprises a compound having angiotensin II antagonistic activity of the formula ##STR16## wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with hydrochlorothiazide or manidipine hydrochloride.

2. The composition claimed in claim 1, in which R.sup.1 is an optionally substituted lower alkyl or lower cycloalkyl.

3. The composition claimed in claim 2, in which R.sup.1 is ethyl.

4. The composition claimed in claim 1, in which R.sup.1 is ethyl and Y is --O--.

5. The composition claimed in claim 1, in which R.sup.2 is a group represented by the --CO--D" (wherein D" stands for hydroxyl or a lower alkoxy whose alkyl moiety is optionally substituted with hydroxyl, amino, halogen, lower alkanoyloxy, lower cycloalkanoyloxy, lower alkoxycarbonyloxy, lower cycloalkoxycarbonyloxy or lower alkoxy).

6. The composition claimed in claim 5, in which R.sup.2 is a lower alkoxycarbonyl optionally substituted with cyclohexyloxycarbonyloxy.

7. The composition of claim 1, in which R.sup.3 is an optionally substituted 5-7 membered monocyclic heterocyclic residue having a hydrogen atom capable of leaving as a proton.

8. The composition claimed in claim 7, in which R.sup.3 is ##STR17##

9. The composition claimed in claim 8, in which R.sup.3 is tetrazolyl.

10. The composition claimed in claim 8, in which R.sup.3 is 2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl.

11. The composition claimed in claim 1, in which R.sup.2 is a lower alkoxycarbonyl substituted with cyclohexyloxycarbonyloxy and R.sup.3 is tetrazolyl.

12. The composition of claim 1, in which R.sup.1 is a lower alkyl and Y is --O--, R.sup.2 is a lower alkoxycarbonyl substituted with cyclohexyloxycarbonyloxy, and R.sup.3 is tetrazolyl.

13. The composition of claim 1, in which the compound represented by the formula (I) is 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7 -carboxylic acid.

14. The composition of claim 1, in which the compound represented by the formula (I) is pivaloyloxymethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyt-4-yl]methyl]-1H-benzimidazole-7 -carboxylate.

15. A method for the prophylaxis or treatment of hypertension in a mammal in need thereof which comprises administering an effective amount of a compound having angiotensin II antagonistic activity represented by the formula (I) wherein R.sup.1 is H or an optionally substituted hydrocarbon residue; R.sup.2 is an optionally esterified carboxyl group; R.sup.3 is a group capable of forming an anion or a group convertible thereinto; X is a covalent bond between the 2 phenyl rings or a spacer having a chain length of 1 to 2 atoms as the linear moiety between the adjoining phenylene group and phenyl group; n is 1 or 2; the ring A is a benzene ring having 1 or 2 optional substituents in addition to R.sup.2 ; and Y is a bond, --O--, --S(O)m- (wherein m is 0, 1 or 2) or --N(R.sup.4)-- (wherein R.sup.4 is H or an optionally substituted alkyl group), or a pharmaceutically acceptable salt thereof in combination with an effective amount of hydrochlorothiazide or manidipine hydrochloride.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc